IL-35+Breg/Il-35 Effect on T Cell Immune in Patients With CHB
- Conditions
- Chronic Hepatitis b
- Registration Number
- NCT03734783
- Lead Sponsor
- Changhai Hospital
- Brief Summary
The investigators observed the level of IL-35 secreting B regulatory (IL-35+Bregs) cells in peripheral blood cells in patients with chronic hepatitis B, and analysed the relationship between the IL-35+Bregs level and disease stage, and Th1 and Th2 cells level.
- Detailed Description
Regulatory B cells (Bregs) are involved in the immune tolerance process through multiple pathways and Bregs are involved in the process of chronic HBV infection.
Here the investigators intended to investigate the regulating role and the mechanism of CD19+ IL-35+ cells on host T cell immune during chronic HBV infection by using in vitro cell sorting, B cell differentiation induction, Transwell cell co-culture system and other methods.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 55
- Clinical diagnosis of chronic hepatitis B virus infection
- 17<age<70
- Can read, understand and sign patients informed consent
- Co-infection with HCV,HIV,HDV etc.
- Have malignancy
- Have uncontrollable extra-hepatic disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method IL-35+Bregs regulatory effect enrolled day regulatory effect of IL-35+Bregs on T cell immune
IL-35+Bregs level ENROLLED DAY IL-35 secreting regulatory B cells level in patients with CHB
- Secondary Outcome Measures
Name Time Method IL-35+Bregs phenotype enrolled day the main phenotype of IL-35 secreting Bregs
Trial Locations
- Locations (1)
Changhai hospital
🇨🇳Shanghai, China